AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Participating in the Blue Cross Blue Shield Alliance for Health Research, the study comes from Yale’s School of Public Health and School of Medicine NEW HAVEN, Conn., March 22, 2019 /PRNewswire/ –State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say […]
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.
The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche AG’s blockbuster breast cancer treatment Herceptin.
The U.S. Food and Drug Administration granted accelerated approval to Roche’s Genentech for Tecentriq (atezolizumab) plus chemotherapy (nab-paclitaxel) to treat unresectable locally advanced or metastatic triple-negative breast cancer in patients whose tumors expressed PD-L1.
Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.
The U.S. Food and Drug Administration approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment Herceptin.
The U.S. Food and Drug Administration declined to grant accelerated approval for Immunomedics Inc.’s breast cancer treatment sacituzumab.
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.